JHOP - September 2018 Vol 8, No 3

Nathan M. Kawamura, PharmD, BCOP, and colleagues assess the reasons for dose reductions and treatment discontinuation in patients who receive oral chemotherapy for metastatic kidney cancer.

This single-institution study led by Caroline Townley, PharmD, compares the use of the Onpro device and the manual injection of pegfilgrastim and discusses the potential implications of the findings.

The authors describe a case of an undetectable everolimus level in a patient with kidney cancer who received phenobarbital and was hospitalized because of heart failure.

This symptom management article describes the approach to rasburicase-induced hemolytic anemia in patients with glucose-6-phosphate dehydrogenase deficiency, which may occur intravascularly in this patient population.


Results 1 - 4 of 4